Discover Top Posts Tagged with #tirbanibulin

Tirbanibulin superior to placebo for actinic keratosis

(HealthDay)—Tirbanibulin is superior to vehicle at two months for the treatment of actinic keratosis, but almost half of patients who had a complete response experienced recurrence of lesions at one year, according to a study published in the Feb. 11 issue of the New England Journal of Medicine. Andrew Blauvelt, M.D., from the Oregon Medical Research Center in Portland, and colleagues randomly…